Menu
Recruiting NCT07428629

Piloting an Insomnia Treatment in Patients With Ulcerative Colitis

No phase Interventional Insomnia Ulcerative Colitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CBT-I UC.
Who it may be relevant to
Registry conditions: Insomnia, Ulcerative Colitis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this clinical trial is to learn if telehealth-based Cognitive Behavioral Therapy for Insomnia (CBT-I) adapted for Ulcerative Colitis (UC) works to treat insomnia in adults with UC. The main questions it aims to answer are: * Is telehealth-based CBT-I adapted for UC feasible and acceptable to participants? * Does CBT-I for UC impact insomnia severity and sleep continuity? Participants will: * Answer questionnaires online before and after treatment * Complete an online daily sleep diary before, during, and after treatment * Participate in 5 telehealth treatment visits over 7-8 weeks * Participate in 5-10-minute phone calls between treatment visits

Interventions

  • Behavioral CBT-I UC
    This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.

Primary outcome measures

  • Retention [Time frame: Baseline, 8 weeks]
  • Recruitment rate [Time frame: From study initiation until we are no longer actively recruiting (approximately 3 months)]
  • Acceptability [Time frame: 8 weeks]
  • Treatment acceptability questionnaire score [Time frame: 1 week]
Secondary outcome measures (4)
  • Change in insomnia symptoms as measured by the Insomnia Severity Index [Time frame: Baseline, 8 weeks]
  • Change in diary-based sleep onset latency [Time frame: Baseline, 8 weeks]
  • Change in diary-based wake after sleep onset [Time frame: Baseline, 8 weeks]
  • Change in diary-based sleep efficiency [Time frame: Baseline, 8 weeks]

Eligibility criteria

Inclusion criteria

  • Active UC based on PRUCSI
  • Insomnia Severity Index score > 8 and SOL or WASO > 30 minutes
  • Stability of sleep \& UC meds for > 3 months
  • Access to internet or cell phone service sufficient for telehealth

Exclusion criteria

  • PHQ-9 depression score > 15
  • GAD-7 anxiety score > 15
  • Unstable major psychiatric condition (e.g., bipolar disorder, psychotic disorder)
  • Current alcohol or substance abuse
  • Current opioid use for pain control
  • Current systemic corticosteroid use
  • Current pregnancy or nursing
  • Ileostomy or colostomy
  • Diagnosis of seizure disorder
  • Diagnosis of sleep apnea
  • Diagnosis of restless leg syndrome or positive Cambridge-Hopkins RSLq screen
  • Night shift, rotating shift work, or frequent travel outside of time zone
  • Residence in a state where we cannot conduct telehealth visits

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Dartmouth-Hitchcock Medical Center — Lebanon

Identifiers

NCT: NCT07428629 · STUDY02003289

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗